Should you buy Tenaya Therapeutics stock now?
No, the technical signal for Tenaya Therapeutics is currently SELL. Tenaya Therapeutics trades at $0.75 as of 8/11/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.016 with falling momentum (signal: -0.010); RSI is at 44.2 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $3.20 points to 328.5% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Tenaya Therapeutics stock?
The average analyst price target for Tenaya Therapeutics is $3.20. The current price is $0.75, which gives an upside of 328.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $2.88 and $3.52.
Is Tenaya Therapeutics a dividend stock?
No, Tenaya Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Tenaya Therapeutics stock?
Tenaya Therapeutics is rated as a stock with low risk. the annual standard deviation is 0.0%, which classifies the stock as low risk.
Is Tenaya Therapeutics overvalued?
No, Tenaya Therapeutics is considered undervalued based on the analyst price target (328.5% upside). Tenaya Therapeutics has the following valuation ratios: a P/S ratio of 724.3, a P/B ratio of 2.3. The analyst price target suggests that the stock is undervalued by 328.5%.
Is Tenaya Therapeutics overbought?
No, Tenaya Therapeutics is not overbought. RSI is at 44.2 (neutral zone). The technical indicators show: RSI is at 44.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.9% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Tenaya Therapeutics earnings report?
The date of the next earnings report for Tenaya Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Tenaya Therapeutics shorted?
Yes, Tenaya Therapeutics is shorted with 14.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Tenaya Therapeutics stock?
No, insiders are not buying Tenaya Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 6,317 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 2,812,450 $ sold. Active sellers include Tingley Whittemore, Higa Tomohiro, Ali Faraz and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Tenaya Therapeutics a good stock?
We do not yet have enough data to give Tenaya Therapeutics an overall rating. In addition: analysts see 328.5% upside to the price target; technical signal: Strong Sell. Whether Tenaya Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Tenaya Therapeutics stock?
The outlook for Tenaya Therapeutics based on current data: the average analyst price target is $3.20 (+328.5%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Tenaya Therapeutics stock falling?
Tenaya Therapeutics is falling right now. The technical indicators show: the price is 3.9% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 14.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Tenaya Therapeutics go?
The average analyst price target for Tenaya Therapeutics is $3.20, which corresponds to a potential gain of 328.5% from the current price of $0.75. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Tenaya Therapeutics fall?
We lack enough history to give a specific floor for Tenaya Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Tenaya Therapeutics do?
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopath... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Tenaya Therapeutics as an investment.
Did Tenaya Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Tenaya Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Tenaya Therapeutics making money or losing money?
We have no current profitability data for Tenaya Therapeutics. See the latest report in the earnings history above.
Can Tenaya Therapeutics go bankrupt?
The bankruptcy risk of Tenaya Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -22.96 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 29% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Tenaya Therapeutics have a lot of debt?
No, Tenaya Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 29%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.